Insight Folios Inc Purchases New Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Insight Folios Inc purchased a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 659 shares of the biotechnology company’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. LPL Financial LLC grew its holdings in Axon Enterprise by 6.6% in the third quarter. LPL Financial LLC now owns 43,559 shares of the biotechnology company’s stock worth $8,668,000 after purchasing an additional 2,715 shares during the period. Stifel Financial Corp grew its holdings in Axon Enterprise by 2.4% in the third quarter. Stifel Financial Corp now owns 21,961 shares of the biotechnology company’s stock worth $4,370,000 after purchasing an additional 506 shares during the period. Advisors Asset Management Inc. grew its holdings in Axon Enterprise by 18.9% in the third quarter. Advisors Asset Management Inc. now owns 18,650 shares of the biotechnology company’s stock worth $3,711,000 after purchasing an additional 2,965 shares during the period. Ameriprise Financial Inc. grew its holdings in Axon Enterprise by 10.1% in the third quarter. Ameriprise Financial Inc. now owns 379,286 shares of the biotechnology company’s stock worth $75,474,000 after purchasing an additional 34,728 shares during the period. Finally, Kennedy Capital Management LLC grew its holdings in Axon Enterprise by 4.4% in the third quarter. Kennedy Capital Management LLC now owns 48,360 shares of the biotechnology company’s stock worth $9,623,000 after purchasing an additional 2,047 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on AXON shares. JMP Securities restated a “market outperform” rating and issued a $375.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a report on Tuesday, May 7th. StockNews.com cut shares of Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Craig Hallum increased their price target on shares of Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, Morgan Stanley increased their price target on shares of Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Insiders Place Their Bets

In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the transaction, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Jeri Williams sold 308 shares of the firm’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total transaction of $95,501.56. Following the sale, the director now directly owns 1,607 shares in the company, valued at approximately $498,282.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 993 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the transaction, the director now directly owns 4,553 shares of the company’s stock, valued at $1,282,671.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,447 shares of company stock worth $27,684,677. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Stock Up 1.2 %

Shares of Axon Enterprise stock opened at $296.56 on Friday. The company has a market cap of $22.38 billion, a price-to-earnings ratio of 86.71 and a beta of 0.95. The company’s 50 day moving average is $294.68 and its 200 day moving average is $285.92. Axon Enterprise, Inc. has a twelve month low of $175.37 and a twelve month high of $329.87. The company has a quick ratio of 2.55, a current ratio of 2.91 and a debt-to-equity ratio of 0.37.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. During the same period last year, the firm earned $0.51 earnings per share. The company’s quarterly revenue was up 34.3% on a year-over-year basis. Research analysts anticipate that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.